Informed Consent in a Clinical Trial: What the Document Must Say (2026)

What must a clinical trial informed consent document say? An informed consent document (often called an informed consent form, or ICF) is the written part of the process by which a person agrees to take part in a clinical trial after being told, in language they understand, what the study involves. The document must give a participant enough honest, clear information to make a free choice, and it must do so without pressure, false hope or legalese. Across the main rule sets (the US FDA regulations, the international ICH Good Clinical Practice guideline, and India's rules), a compliant consent document generally must cover the items below. This is general guidance, not legal or medical advice; the exact wording and required elements depend on the governing law, the ethics committee or institutional review board, and the specific trial. Last verified October 2026. ## The core elements every consent document should contain 1. A statement that the study involves research, and that participation is voluntary.

2. The purpose of the research, in plain language.
3. The expected duration of the person's participation.
4. A description of the procedures, with any that are experimental clearly marked.
5. Reasonably foreseeable risks or discomforts to the participant (and, where relevant, to an embryo, foetus or nursing infant).
6. Expected benefits, to the participant or to others, stated honestly and without overstatement. It is acceptable, and often correct, to say there may be no direct benefit.
7. Appropriate alternative treatments or procedures that might help the person, if any.
8. How confidentiality will be protected, and who may inspect the records (such as the sponsor, the ethics committee and regulators).
9. Whether any compensation or medical treatment is available if injury occurs, and what it consists of.
10. Who to contact for questions about the study, about the participant's rights, and in the event of a research-related injury.
11. A clear statement that participation is voluntary, that refusal carries no penalty or loss of benefits the person is otherwise entitled to, and that the person may withdraw at any time without penalty. ## "When appropriate" elements to add Some elements are required only when they fit the study: - Risks that are currently unforeseeable.

• Circumstances under which the investigator may end a person's participation without their consent.
• Any additional costs the person may face.
• The consequences of withdrawing, and procedures for an orderly withdrawal.
• A statement that significant new findings developed during the study, which may affect willingness to continue, will be shared.
• The approximate number of participants in the study. The ICH Good Clinical Practice guideline (E6) asks for a longer list still, including the probability of being assigned to each arm of the study (for example in a randomised trial), a description of the participant's own responsibilities, and the signature of the person who obtained consent, not just the participant. ## India-specific requirements India's New Drugs and Clinical Trials Rules, 2019 (which carried forward much of the earlier Schedule Y practice) add their own requirements on top of the general elements: - Consent must be freely given, informed and in writing, obtained from each participant.
• The investigator must explain the study verbally and provide a patient information sheet in a language the participant actually understands, in non-technical terms.
• If the participant, or their legally acceptable representative, cannot read or write, an impartial witness must be present throughout the consent process and sign the form.
• For vulnerable participants in trials of a new chemical entity or new molecular entity, an audio-video recording of the consent process is required. ## Red flags in a consent document - Overstated benefit or understated risk. Language that sounds like a sales pitch is a warning sign.
• Waiver of legal rights. A consent document cannot ask a person to waive, or appear to waive, their legal rights, or release the sponsor, investigator or institution from liability for negligence.
• Coercive or pressuring language, or anything that makes withdrawal sound difficult or risky.
• Technical or legal jargon a layperson cannot follow. Consent is not informed if the person cannot understand the document.
• No clear injury or contact information.
• A single document doing too much, so that key risks are buried. ## A note on jurisdiction The frameworks overlap but are not identical. The United States follows the FDA regulations (and, for federally funded research, the Common Rule); international multi-country trials follow ICH Good Clinical Practice; the European Union applies the Clinical Trials Regulation; and India applies the New Drugs and Clinical Trials Rules, 2019 under oversight of the Central Drugs Standard Control Organisation. A trial running in several countries usually builds one consent document that satisfies the strictest applicable rules, then translates and adapts it for each site and ethics committee. Requirements change over time, so the current official text and your ethics committee's own template should always be checked. ## Where a contract and document workspace helps An informed consent document is one of a family of trial documents (the protocol, the investigator agreement, site and vendor contracts, data-processing terms) that all have to stay consistent, versioned and compliant across many sites. The hard part is rarely writing the first draft; it is keeping every version aligned, catching missing required elements, and never losing track of which document an ethics committee approved. That is the idea behind a single AI document and contract workspace. It can model a document as a structured tree rather than flat text, flag missing or weak items, let a reviewer edit in plain language and see a clean diff, and keep a live timeline of every version and approval. Tools such as Adira are built around that one-workspace idea. This checklist alone is enough to sanity-check a consent document against the required elements; a workspace simply keeps drafting, review, versioning and compliance connected rather than scattered across files.